Certificate of Analysis
Third Party Tested
Molecular Profile
Compound
CJC 1295 No DAC
Batch #
N/A
Formula
C152H252N44O42
Mol Wt
3367.9 g/mol
CAS
863288-34-0
Latest
ISO 17025
8× Testing
99.5%
Purity
VariantCJC 1295
COA ##13136
Labeled10mg
Validation KeyAXISBIOTECH
Tested05/12/26
Full QC Panel - 8× tested
✓
Purity (HPLC) - 99.5%
✓
Net Peptide Content - 10mg
✓
Identity (HPLC) - CJC 1295
✓
Fentanyl Screen - Not Detected
✓
HPLC Conformity mean - >99%
✓
ISO/IEC 17025 Accredited
Storage Requirements
Stability Information
Lyophilized (powder)
−20°C long-term
2–8°C
Reconstituted
Recommended condition
Light protection
Store away from light
Sealed lyophilized vials are heat-stable; refrigerating or freezing sealed vials is optional. 2–8°C applies to reconstituted solutions.
Peer-Reviewed Literature
Research & References
Research and reference material related to this compound.
01
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
02
CJC-1295, a long-acting growth hormone releasing factor analog
03
Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly
04
Growth hormone-releasing hormone: signal transduction, gene expression, and physiological effects
05
Long-acting growth hormone analogs and growth hormone-releasing factor analogs
Safety & Regulatory Compliance Warning
These products are intended solely for laboratory research and analytical applications. They have not been evaluated by the U.S. Food and Drug Administration (FDA) and are not approved for therapeutic use, diagnosis, treatment, or prevention of disease. Under no circumstances should these materials be used for human or animal consumption.
